COVID and Lung Cancer.
COVID-19: SARS-CoV-2; Lung cancer
Drug-toxicity pneumonitis
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
22 10 2021
22 10 2021
Historique:
accepted:
02
09
2021
entrez:
22
10
2021
pubmed:
23
10
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Since the past year, the fast spread of coronavirus disease 2019 (COVID-19) has represented a global health threat, especially for cancer patients, that has required an urgent reorganization of clinical activities. Here, we will critically revise the profound impact that the pandemic has generated in lung cancer patients, as well the most significant challenges that oncologists have to face to maintain the highest possible standards in the management of lung cancer patients in the pandemic era. Evidences suggested a higher susceptibility and mortality of lung cancer patients due to COVID-19. The hard management of this patient population has been also due to the potential cross interference of anti-tumor drugs on SARS-Cov-2 infection and to the differential diagnosis between COVID-19 pneumonitis and drug-related pneumonitis. COVID-19 pandemic has generated a profound reshaping of oncological activities and the development of recommendations by the oncology scientific community to prioritize anti-tumor treatments for lung cancer patients.
Identifiants
pubmed: 34677721
doi: 10.1007/s11912-021-01125-8
pii: 10.1007/s11912-021-01125-8
pmc: PMC8532085
doi:
Substances chimiques
Antineoplastic Agents
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
134Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
Ann Intern Med. 2020 Jun 2;172(11):756-758
pubmed: 32219410
Semin Oncol. 2015 Aug;42(4):601-16
pubmed: 26320064
J Infect Dis. 2020 May 11;221(11):1770-1774
pubmed: 32179910
J Clin Oncol. 2017 Mar;35(7):709-717
pubmed: 27646942
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Lung Cancer. 2018 Dec;126:149-155
pubmed: 30527179
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Future Oncol. 2020 Oct;16(29):2265-2268
pubmed: 32659118
Ann Palliat Med. 2020 Sep;9(5):3373-3378
pubmed: 33065788
Tumori. 2021 Jun;107(3):267-269
pubmed: 32842909
Lancet Respir Med. 2020 Jun;8(6):542-544
pubmed: 32278368
Lancet Oncol. 2021 Feb;22(2):198-211
pubmed: 33476593
Clin Cancer Res. 2020 Aug 15;26(16):4201-4205
pubmed: 32540850
J Cancer. 2020 Jul 9;11(18):5289-5292
pubmed: 32742475
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
N Engl J Med. 2020 May 21;382(21):2049-2055
pubmed: 32202722
Emerg Infect Dis. 2020 May;26(5):1024-1027
pubmed: 32150528
Physiol Genomics. 2020 Nov 1;52(11):549-557
pubmed: 32991251
JCO Glob Oncol. 2020 Sep;6:1428-1438
pubmed: 32986516
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Expert Rev Anti Infect Ther. 2020 Sep;18(9):843-847
pubmed: 32419524
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Cardiovasc Res. 2020 Dec 1;116(14):2177-2184
pubmed: 32750108
J Korean Med Sci. 2019 Jan 04;34(3):e18
pubmed: 30662384
Ann Oncol. 2020 Oct;31(10):1386-1396
pubmed: 32561401
Clin Infect Dis. 2020 Nov 19;71(16):2199-2206
pubmed: 32407459
Lung Cancer. 2019 Aug;134:127-140
pubmed: 31319971
N Engl J Med. 2003 May 15;348(20):1967-76
pubmed: 12690091
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Nat Cancer. 2020 Aug;1(8):784-788
pubmed: 35122051
J Med Virol. 2020 Sep;92(9):1684-1689
pubmed: 32343415
Nat Rev Clin Oncol. 2020 May;17(5):268-270
pubmed: 32242095
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
Eur Radiol. 2020 Sep;30(9):4903-4909
pubmed: 32314058
Eur J Pharmacol. 2020 Sep 15;883:173372
pubmed: 32682787
Clin Cancer Res. 2016 Dec 15;22(24):6051-6060
pubmed: 27535979
Acta Oncol. 1990;29(2):113-24
pubmed: 2185802
ESMO Open. 2020 Jun;5(Suppl 3):
pubmed: 32581069
N Engl J Med. 2020 Aug 27;383(9):887
pubmed: 32678532
Ann Oncol. 2020 Jan;31(1):50-60
pubmed: 31912796
Radiology. 2020 Aug;296(2):E97-E104
pubmed: 32339082
Immunity. 2007 Oct;27(4):670-84
pubmed: 17950003
Euro Surveill. 2020 Mar;25(11):
pubmed: 32209163
N Engl J Med. 2020 Jun 11;382(24):2285-2287
pubmed: 32267650
Medicine (Baltimore). 2020 Jan;99(5):e19013
pubmed: 32000444
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
J Thorac Oncol. 2018 Dec;13(12):1930-1939
pubmed: 30267842
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet Oncol. 2020 May;21(5):629-630
pubmed: 32247319
Am J Public Health. 2021 Jun;111(6):1061-1064
pubmed: 33539177
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Postgrad Med J. 2021 May;97(1147):312-320
pubmed: 32978337
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
Lancet Oncol. 2021 Mar;22(3):305
pubmed: 33549163
J Immunother Cancer. 2019 Dec 17;7(1):353
pubmed: 31847881
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
Radiology. 2020 Dec;297(3):E335-E338
pubmed: 32407256
J Infect Public Health. 2020 Nov;13(11):1619-1629
pubmed: 32718895
Natl Sci Rev. 2020 Jun;7(6):998-1002
pubmed: 34676125
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Front Oncol. 2020 Oct 29;10:577696
pubmed: 33194697
Biomed Pharmacother. 2020 Nov;131:110678
pubmed: 32861070
Cancers (Basel). 2020 Aug 10;12(8):
pubmed: 32785162
ESMO Open. 2020 Mar;5(2):
pubmed: 32229501
Cancer Treat Rev. 2020 Aug;88:102041
pubmed: 32516704
Br J Cancer. 2020 Jul;123(1):5-6
pubmed: 32313215